Bulevirtide
A 47-residue myristoylated lipopeptide derived from the hepatitis B virus preS1 domain that blocks the NTCP entry receptor, approved in the European Union since 2020 and by the FDA in May 2026 as Hepcludex for chronic hepatitis delta.
Also referenced as: Myrcludex B, Hepcludex, bulevirtide acetate, bulevirtide-gmod
Public product evidence No certificate records are bound to a tracked Bulevirtide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Bulevirtide product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Myrcludex B, Hepcludex, bulevirtide acetate, bulevirtide-gmod
FDA label signal · 30 trials · 331 PubMed results
Bulevirtide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Bulevirtide has 23 name-matched clinical trials (highest phase: Phase 3) and 331 PubMed-indexed publications and holds an FDA drug label. 8 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Bulevirtide?
Bulevirtide is a synthetic 47-residue lipopeptide whose sequence reproduces the N-terminal part of the preS1 domain of the hepatitis B virus large surface protein, the stretch the virus itself uses to dock onto liver cells. The US prescribing information describes it as a 47-amino-acid protein carrying a myristoyl fatty-acid residue at the N-terminus and an amidated C-terminus, with all chiral amino acids in the L-configuration, supplied as an acetate salt. The lipid tail anchors the peptide in the hepatocyte membrane so the preS1 segment, which structural work maps to residues 2 through 48, can engage the sodium taurocholate cotransporting polypeptide (NTCP), the bile salt transporter that serves as the receptor for both hepatitis B and hepatitis delta virus (Watashi et al., Nature Reviews Microbiology, 2025).
The compound began as Myrcludex B in Stephan Urban’s laboratory at Heidelberg University, moved through early clinical development with MYR GmbH and Hepatera, and has been developed by Gilead Sciences, which now owns MYR GmbH. Its target disease is chronic hepatitis delta, the most aggressive form of chronic viral hepatitis: hepatitis delta virus cannot envelope itself without hepatitis B surface antigen, so it infects only people who already carry hepatitis B, and coinfection speeds progression to cirrhosis and liver cancer. Bulevirtide is the first drug approved anywhere for that infection, marketed as Hepcludex in the European Union since 2020 and in the United States since May 2026. It belongs to the small group of approved antiviral peptides that act outside the cell, alongside the HIV fusion inhibitor Enfuvirtide, and has no footprint in the research-peptide market.
How it works
- Occupies the viral entry receptor. NTCP, encoded by SLC10A1, was confirmed as the specific receptor for hepatitis B and hepatitis delta virus through gene-expression comparison in susceptible and naive HepaRG cells and binding and infection tests in transduced hepatoma lines; the same work showed that Myrcludex B, the peptide ligand derived from the hepatitis B L-protein, binds NTCP and blocks its bile salt transport (Ni et al., Gastroenterology, 2014). The European product information states the mechanism in those terms: bulevirtide binds and inactivates NTCP, blocking entry of both viruses into hepatocytes.
- Empties the liver of infected cells over time. A combined analysis of 126 paired liver biopsies from the MYR202, MYR203 and MYR301 trials found median intrahepatic hepatitis delta RNA declines of 0.9 to 1.4 log10 after 24 weeks and of 2.2 to 2.7 log10 after 48 weeks, with a steep fall in hepatitis delta antigen-positive hepatocytes and in inflammatory chemokine and interferon-stimulated gene transcription, while hepatitis B covalently closed circular DNA was unchanged (Allweiss et al., Journal of Hepatology, 2024).
- Raises bile salts as an on-target effect. In MYR301 every participant given bulevirtide had elevated serum bile salts, peaking by week 8 and rising with dose (Wedemeyer et al., New England Journal of Medicine, 2023). The European label calls these elevations asymptomatic, notes that they resolve after treatment stops, and warns they may be larger when renal function is impaired, since bile salts are excreted renally.
- Target-mediated pharmacokinetics. Exposure follows a two-compartment target-mediated drug disposition model, subcutaneous bioavailability is about 85%, and the model implies more than 80% target saturation for at least 15 hours at subcutaneous doses of 10 mg and above (Blank et al., Journal of Hepatology, 2016).
Research status
Phase 1. The first-in-human trial gave single ascending doses up to 20 mg intravenously and 10 mg subcutaneously to 36 healthy volunteers, with no serious or off-target adverse effects and no immunogenicity (Blank et al., Journal of Hepatology, 2016).
Phase 2 (MYR202 and MYR203). MYR203 (NCT02888106), sponsored by Hepatera, enrolled 90 patients into six arms of 15 testing peginterferon alfa-2a alone, bulevirtide at 2, 5 or 10 mg daily with peginterferon alfa-2a, bulevirtide 2 mg alone, and bulevirtide 10 mg with tenofovir disoproxil fumarate, each for 48 weeks. At the primary endpoint 24 weeks later, undetectable hepatitis delta RNA was reached by 53% on 2 mg plus peginterferon, 33% on 10 mg plus tenofovir, 27% on 5 mg plus peginterferon and 7% on either 2 mg alone or 10 mg plus peginterferon, against 0% on peginterferon alone; four patients lost hepatitis B surface antigen, all on 2 mg plus peginterferon (Lampertico et al., Liver International, 2025). MYR202 (NCT03546621) tested 24 weeks of treatment.
MYR301 phase 3 (NCT03852719). The pivotal open-label trial randomized 150 patients with chronic hepatitis delta, with or without compensated cirrhosis, in a 1:1:1 ratio to bulevirtide 2 mg daily, 10 mg daily, or no treatment for 48 weeks followed by 10 mg daily for 96 weeks. The primary endpoint, a combined week 48 response of undetectable hepatitis delta RNA or a decline of at least 2 log10 IU/mL plus alanine aminotransferase normalization, was met by 45% on 2 mg, 48% on 10 mg and 2% of controls (P<0.001 for each comparison). Hepatitis delta RNA was undetectable in 12% and 20% (P = 0.41), alanine aminotransferase normalized in 51% and 56% against 12% of controls, and no treated patient lost hepatitis B surface antigen by week 48 (Wedemeyer et al., New England Journal of Medicine, 2023). Week 96 results sustained the pattern (Wedemeyer et al., Journal of Hepatology, 2024). The final report added 144 weeks of treatment and 96 weeks of follow-up: at the end of treatment, virologic response reached 73 to 92% across the three groups, alanine aminotransferase normalized in 58 to 60%, combined response was 54 to 57% and hepatitis delta RNA was undetectable in 29 to 52%. By the last follow-up visit, virologic response had fallen to 30 to 33%, combined response to 24% and undetectability to 20 to 22%; only 23 of 64 patients (36%) who ended treatment with undetectable RNA stayed undetectable, and post-treatment hepatic serious adverse events occurred in 20 of 142 patients (14%), resolving in 17 of 20 (Wedemeyer et al., Journal of Hepatology, 2026).
MYR204 combination phase 2b (NCT03852433). This open-label trial assigned 24 patients to peginterferon alfa-2a alone, 50 each to bulevirtide 2 mg or 10 mg plus peginterferon followed by bulevirtide alone, and 50 to bulevirtide 10 mg alone. Undetectable hepatitis delta RNA 24 weeks after the end of treatment, the primary endpoint, was reached by 17%, 32%, 46% and 12% respectively, making the combination superior to monotherapy by 34 percentage points (95% CI 15 to 50; P<0.001); at 48 weeks after treatment the rates were 25%, 26%, 46% and 12%. Leukopenia, neutropenia and thrombocytopenia were the most frequent adverse events (Asselah et al., New England Journal of Medicine, 2024).
Resistance and pooled safety. No virologic resistance was detected through 24 weeks of treatment across the phase 2 and phase 3 programs (Hollnberger et al., Journal of Hepatology, 2023). An integrated week 48 safety analysis of MYR203, MYR204 and MYR301 compared 64 patients on 2 mg and 115 on 10 mg with 51 untreated controls: increased total bile acids (20% and 17% against 0%), injection-site reactions, headache, pruritus and eosinophilia were the excess events, grade 3 or 4 drug-related events occurred in 3% and 4% against 51% of patients on peginterferon alfa-2a, and there were no bulevirtide-related serious adverse events, no hepatic decompensation and no deaths (Asselah et al., Liver International, 2025).
Real-world cohorts. An Austrian multicenter cohort reported response-guided long-term outcomes early in European use (Jachs et al., Alimentary Pharmacology and Therapeutics, 2022), and the Italian compassionate-use program reported three years of monotherapy in hepatitis delta-related compensated cirrhosis (Anolli et al., Digestive and Liver Disease, 2026). A Karolinska observational study (NCT06051045) runs to March 2033.
Regulatory path. The European Commission granted a conditional marketing authorization on July 31, 2020, converted to a standard one on July 18, 2023 after the sponsor supplied confirmatory information. In the United States the first application was turned down: a complete response letter announced on October 27, 2022 cited the manufacture and delivery of the product, and no additional efficacy or safety studies were requested. BLA 761468 was then approved on May 22, 2026 under the accelerated approval pathway. Bulevirtide is also approved in the United Kingdom, Switzerland, the Russian Federation, Australia and Canada (Wedemeyer et al., Journal of Hepatology, 2026).
Current activity. A sponsor-run post-marketing registry (NCT05718700) closed on August 31, 2026 after 170 participants, terminated by sponsor decision with no safety concerns. Bulevirtide now serves as the comparator for competing programs, including the phase 3 AZURE-2 trial of brelovitug (NCT07200908, primary completion estimated June 30, 2027) and a phase 2 trial of tobevibart with elebsiran (NCT07142811).
Common dosage forms
- Hepcludex (bulevirtide-gmod) for injection, 8.5 mg (US). A white to off-white lyophilized powder or cake in a single-dose vial delivering 8.5 mg of bulevirtide-gmod, equivalent to about 8.6 mg of bulevirtide acetate, for subcutaneous use, in cartons of 30 vials.
- Hepcludex 2 mg powder for solution for injection (European Union). A white to off-white powder in a colorless glass vial containing bulevirtide acetate equivalent to 2 mg of bulevirtide, for subcutaneous use, in packs of 30 vials.
- No other presentation. No oral, nasal, depot or compounded form exists.
Key considerations
- Regulatory status. The FDA Approved status reflects the May 22, 2026 accelerated approval of Hepcludex (bulevirtide-gmod) for injection under BLA 761468 for chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. That approval followed a complete response letter announced on October 27, 2022 that concerned the manufacture and delivery of the product rather than its trial evidence, and the European authorization preceded it by nearly six years.
- Approval rests on surrogate endpoints. The US label states that accelerated approval was based on a decrease in hepatitis delta RNA and normalization of alanine aminotransferase, that improvement in disease-related clinical outcomes has not been established, and that continued approval may be contingent on confirmatory trials.
- Stopping treatment is the main hazard. The label carries a boxed warning for severe acute exacerbation of hepatitis D and B after discontinuation, worse in patients with cirrhosis, and the 144-week MYR301 report recorded post-treatment hepatic serious adverse events in 14% of patients alongside a sharp fall in response rates. Only about a third of those who stopped with undetectable virus stayed that way.
- Bile salt elevations come with the mechanism. Blocking NTCP blocks its normal job, so nearly universal, dose-dependent, reversible rises in serum bile salts are expected rather than idiosyncratic, and the European label flags larger rises in renal impairment. The pooled analysis found no clear link to pruritus, eosinophilia or vitamin D deficiency.
- Regional labels differ, and hepatitis B persists. The US vial is 8.5 mg and the European vial is 2 mg, so strengths are not interchangeable between regions, and the European indication extends to children 3 years and older weighing at least 10 kg while the US indication covers adults only. Bulevirtide suppresses hepatitis delta without clearing its helper virus, as no participant lost hepatitis B surface antigen by week 48 in MYR301.